Nelfinavir
- Generic Name
- Nelfinavir
- Brand Names
- Viracept
- Drug Type
- Small Molecule
- Chemical Formula
- C32H45N3O4S
- CAS Number
- 159989-64-7
- Unique Ingredient Identifier
- HO3OGH5D7I
- Background
Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
- Indication
Used in combination with other antiviral drugs in the treatment of HIV in both adults and children.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Autophagy Maintenance (AUTOMAIN)
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2025-05-14
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 20
- Registration Number
- NCT06971744
Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cannot Be Removed by Surgery
- Conditions
- Stage IIIB Vulvar Cancer AJCC v8Stage II Vulvar Cancer AJCC v8Stage IIIA Vulvar Cancer AJCC v8Stage IIIC Vulvar Cancer AJCC v8Stage III Vulvar Cancer AJCC v8Stage IVA Vulvar Cancer AJCC v8
- Interventions
- First Posted Date
- 2019-11-20
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT04169763
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
- Interventions
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 9
- Registration Number
- NCT03829020
- Locations
- 🇺🇸
Mayo Clinic, Jacksonville, Florida, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2018-02-06
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Registration Number
- NCT03422874
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Cervix
- Conditions
- Carcinoma Cervix,Stage III
- Interventions
- First Posted Date
- 2017-08-22
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Tata Memorial Hospital
- Target Recruit Count
- 348
- Registration Number
- NCT03256916
- Locations
- 🇮🇳
Tata Memorial Centre, Mumbai, Maharashtra, India
Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma
- Conditions
- Recurrent Kaposi SarcomaSkin Kaposi Sarcoma
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2017-03-13
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- AIDS Malignancy Consortium
- Target Recruit Count
- 36
- Registration Number
- NCT03077451
- Locations
- 🇺🇸
Emory University/Grady Hospital, Atlanta, Georgia, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
- Conditions
- Metastatic Kidney CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage IV Cutaneous Melanoma AJCC v6 and v7Stage IV Renal Cell Cancer AJCC v7Stage IV Lung Non-Small Cell Cancer AJCC v7
- Interventions
- Radiation: Hypofractionated Radiation TherapyOther: Laboratory Biomarker AnalysisBiological: NivolumabBiological: Pembrolizumab
- First Posted Date
- 2017-02-10
- Last Posted Date
- 2022-06-22
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 21
- Registration Number
- NCT03050060
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
A Study of Nelfinavir Added to Cisplatin Chemotherapy Concurrent With Pelvic Radiation for Locally Advanced Cervical Cancer (II-IVA)
- First Posted Date
- 2015-02-16
- Last Posted Date
- 2020-04-06
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 6
- Registration Number
- NCT02363829
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Effect of Different Boosting Agents on Pharmacokinetics of BILR 355 BS Dissolved in Polyethylene Glycol 400 (PEG 400) in Healthy Male Volunteers
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-10-06
- Last Posted Date
- 2014-10-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 44
- Registration Number
- NCT02257008
Phase II Trial of Nelfinavir With Concurrent Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Other: Chemoradiation
- First Posted Date
- 2014-08-04
- Last Posted Date
- 2023-07-25
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 18
- Registration Number
- NCT02207439
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.